Drug giants threaten NHS with legal action over cheaper drug that could save £84m a year

The Guardian, 1 November 2017
Author: Sarah Boseley
“Two multinational drug companies are threatening legal action to prevent patients being offered a cheap version of an effective drug against blindness which could save the NHS millions of pounds.”
Find article here.

U.S. states allege broad generic drug price-fixing collusion

Reuters, 1 November 2017
Author: Karen Freifeld
“A large group of U.S. states accused key players in the generic drug industry of a broad price-fixing conspiracy, moving on Tuesday to widen an earlier lawsuit to add many more drugmakers and medicines in an action that sent some company shares tumbling.”
Find article here.

Experts slam ‘utterly false’ claims Australians given budget flu vaccine

SMH, 30 October 2017
Author: Kate Aubusson
“Australia’s Chief Medical Officer has stridently rejected claims a “budget” flu vaccine was partly responsible for this year’s horror flu season, as the academic quoted called the reports “inaccurate”.”
Find article here.

Newly controversial opioid enforcement law under fire

The Hill, 17 October 2017
Author: Rachel Roubein
“Several lawmakers are pushing to repeal or revisit a law critics say enables the flow of deadly and addictive opioids, hours after President Trump’s drug czar nominee withdrew his name amid the controversy.”
Find article here.

California governor signs drug pricing transparency law

Reuters, 10 October 2017
Author: Bill Berkrot
“California Governor Jerry Brown on Monday signed state legislation requiring drug companies to report certain price hikes for prescription medicines in a move that could set a model for other states to follow. The law, which aims to provide more transparency around pharmaceutical and biotech company pricing methods for their medicines, requires drug manufacturers to give a 60-day notice if prices are raised more than 16 percent over a two-year period. The law also requires health plans and insurers to file annual reports outlining how drug costs affect healthcare premiums in California.”
Find article here.

U.S. judge clears way for Maryland drug price-gouging law

Reuters, 30 September 2017
Author: Deena Beasley
“A U.S. District Court judge on Friday cleared the way for Maryland to implement the nation’s first law designed to penalize drugmakers for price gouging by denying the generic drug industry trade group’s request for an injunction.”
Find article here.

FDA plans new compounding pharmacy policy, agency head says

Reuters, 16 September 2017
Author: Nate Raymond
“The head of the U.S. Food and Drug Administration said on Friday the agency is working on a new policy that would encourage more compounding pharmacies to register under a law enacted in the wake of a deadly 2012 meningitis outbreak linked to one such company.”
Find article here.

‘His death still hurts’: the Pfizer anti-smoking drug ruled to have contributed to suicide

The Guardian, 15 September 2017
Author: Andrew McMillen
“When the retired Queensland schoolteacher Phoebe Morwood-Oldham started an online petition following her son’s suicide in April 2013, she could not have known that her insistence on asking hard questions of one of the world’s largest pharmaceutical companies would lead to an Australian-first finding by a state coroner.”
Find article here.

France to prosecute its drug regulator and Servier in scandal over diabetes drug

BMJ 2017; 358: j4231
Author: Owen Dyer
“France’s drug regulator and one of its leading drug companies, Servier, will stand trial as legal persons over the marketing of the antidiabetes and weight loss drug benfluorex (marketed in France as Mediator), which is believed to have killed between 500 and 2300 people before being pulled from the market in 2009.”
Find article here.

A cross-sectional analysis of pharmaceutical industry-funded events for health professionals in Australia

BMJ Open 2017; 7: e016701.
Authors: Fabbri A, Grundy Q, Mintzes B, et al
“To analyse patterns and characteristics of pharmaceutical industry sponsorship of events for Australian health professionals and to understand the implications of recent changes in transparency provisions that no longer require reporting of payments for food and beverages.”
Find article here.